使用家庭干血斑C肽水平早期检测新发1型糖尿病β细胞功能衰退
本研究在新诊断1型糖尿病患者中评估家庭干血斑C肽检测替代混合餐耐量试验的可行性。292例参与者在12个月内居家采集空腹及餐后60分钟干血斑C肽,12个月时行混合餐耐量试验。结果显示,刺激后干血斑C肽前6个月斜率可显著预测12个月静脉混合餐耐量试验C肽曲线下面积和峰值,但空腹干血斑C肽斜率无预测价值。
要点
- 家庭干血斑C肽检测在新诊断1型糖尿病中可行
- 刺激后干血斑C肽前6个月斜率可预测12个月混合餐耐量试验C肽曲线下面积和峰值
- 空腹干血斑C肽斜率不能预测12个月混合餐耐量试验C肽曲线下面积
核心结论
- 家庭干血斑C肽评估是监测新诊断1型糖尿病β细胞功能的可行方法
- 刺激后干血斑C肽的早期预后价值提示其可能优化试验设计
- 需要进一步验证以确认其可靠性和更广泛适用性
研究设计与样本
- 新诊断1型糖尿病患者在诊断后6周内作为INNODIA队列的一部分被招募
- 参与者在家采集空腹和餐后60分钟指尖干血斑C肽数据
- 12个月时进行混合餐耐量试验测量静脉C肽曲线下面积
- 共分析292人的数据,平均年龄12.7岁(范围1.2-43.8岁)
主要发现
- 每参与者12个月内干血斑卡片对中位数为6.5(四分位距=2,9)
- 刺激后干血斑C肽前6个月斜率显著预测12个月静脉混合餐耐量试验C肽曲线下面积和峰值C肽水平(P<0.01)
- 模型校正了同时血糖水平、年龄和基线空腹C肽水平
- 6个月空腹干血斑C肽斜率未预测12个月混合餐耐量试验C肽曲线下面积
临床怎么用
- 原文未据此给出推荐
局限性
- 需要进一步验证以确认家庭干血斑C肽检测的可靠性和更广泛适用性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There is a need for early detection of β-cell decline in people with newly diagnosed (ND) type 1 diabetes. The gold standard mixed-meal tolerance test (MMTT) is an invasive and time-consuming procedure that requires participants to travel to clinical sites. We assessed the feasibility of measuring dried blood spot (DBS) C-peptide levels collected at home as an alternative to the MMTT to detect early β-cell decline. RESEARCH DESIGN AND METHODS: Individuals with ND type 1 diabetes were recruited within 6 weeks of diagnosis as part of the INNODIA cohort. They collected finger-prick DBS C-peptide data at home, both while fasting and 60 min after a liquid meal. At 12 months, an MMTT was conducted to measure the area under the curve (AUC) of venous C-peptide. RESULTS: Data of 292 people were analyzed (mean age 12.7 years; range 1.2-43.8 years). The median number of DBS card pairs per participant was 6.5 (interquartile range = 2, 9) over 12 months. The slopes of stimulated DBS C-peptide levels in the first 6 months significantly predicted venous MMTT AUC C-peptide and peak C-peptide levels at 12 months (P < 0.01). The models were adjusted for simultaneous glucose levels, age, and baseline fasting C-peptide level. However, the 6-month fasting DBS C-peptide slope did not predict 12-month MMTT AUC C-peptide. CONCLUSIONS: Home DBS C-peptide assessment is a feasible method to monitor β-cell function in ND type 1 diabetes. The early prognostic utility of stimulated DBS C-peptide highlights its potential for optimizing trial design. However, further validation is needed to confirm its reliability and broader applicability.
引用
- Hendriks AEJ, Marcovecchio ML, Evans ML, et al. Early Detection of β-Cell Decline Using Home Dried Blood Spot C-Peptide Levels in New-Onset Type 1 Diabetes. Diabetes Care. 2025. PMID: 40402094. doi:10.2337/dc25-0214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。